Inhaling gaseous vinyl chloride

Soft tissue sarcoma - Inhaling gaseous vinyl chloride Factor

Last reviewed for CCPS 20 August 2008.

Investigative Documents

Claimant Report - Inhaling Gaseous Vinyl Chloride [CR9090]

Preliminary questions [22777]

22859

there is some evidence that inhaling gaseous vinyl chloride may be a factor in the development of the condition under consideration.

22781 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and VEA service for the clinical onset of soft tissue sarcoma.

22782 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and operational service for the clinical onset of soft tissue sarcoma.

or

22783 — the veteran has established the causal connection between inhaling gaseous vinyl chloride and eligible service for the clinical onset of soft tissue sarcoma.

Clinical onset and operational service [22782]

27347 the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time.

22785

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration.

22779

operational service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration.

Clinical onset and eligible service [22783]

22778

the condition under consideration is an hepatic angiosarcoma.

27347

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time.

22788

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration.

22787

eligible service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration.